Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H11N3O3S |
Molecular Weight | 253.278 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
InChI
InChIKey=JLKIGFTWXXRPMT-UHFFFAOYSA-N
InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
Molecular Formula | C10H11N3O3S |
Molecular Weight | 253.278 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364668 |
0.71 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
|||
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
|||
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
|||
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
|||
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
|||
Curative | BACTRIM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Launch Date1.12752001E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
94.42 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110016 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFAMETHOXAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
46.3 μg/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM |
SULFAMETHOXAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1202.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20110016 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SULFAMETHOXAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.8 h |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM |
SULFAMETHOXAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: TRIMETHOPRIM |
SULFAMETHOXAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
Disc. AE: Insomnia... Other AEs: Fear, Behaviour abnormal... AEs leading to discontinuation/dose reduction: Insomnia Other AEs:Fear Sources: Behaviour abnormal Visual hallucinations Disorientation Auditory hallucinations |
1600 mg multiple, oral Recommended Dose: 1600 mg Route: oral Route: multiple Dose: 1600 mg Co-administed with:: TRIMETHOPRIM(320 mg; daily) Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: renal transplantation Age Group: adult Population Size: 14 Sources: |
Other AEs: Leucopenia... |
2400 mg 1 times / day single, oral Highest studied dose Dose: 2400 mg, 1 times / day Route: oral Route: single Dose: 2400 mg, 1 times / day Co-administed with:: TRIMETHOPRIM(480 mg; single) Sources: |
unhealthy, mean age 20 years n = 31 Health Status: unhealthy Condition: urinary tract infection Age Group: mean age 20 years Sex: F Population Size: 31 Sources: |
|
1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(240 mg; 2/day) Sources: amphotericin B(800 mg; day) |
unhealthy, mean age 47 years n = 26 Health Status: unhealthy Condition: acute nonlymphocytic leukaemia Age Group: mean age 47 years Population Size: 26 Sources: |
Disc. AE: Allergic reaction... Other AEs: Granulocytopenia... AEs leading to discontinuation/dose reduction: Allergic reaction (3.8%) Other AEs:Granulocytopenia Sources: |
800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, mean age 58 years n = 41 Health Status: unhealthy Condition: urinary infection Age Group: mean age 58 years Sex: M+F Population Size: 41 Sources: |
Disc. AE: Skin rash... AEs leading to discontinuation/dose reduction: Skin rash (4.9%) Sources: |
1200 mg multiple, oral (mean) Studied dose Dose: 1200 mg Route: oral Route: multiple Dose: 1200 mg Co-administed with:: TRIMETHOPRIM(240 mg; day) Sources: |
unhealthy, median age 69 years n = 91 Health Status: unhealthy Condition: septicemia Age Group: median age 69 years Sex: M+F Population Size: 91 Sources: |
Other AEs: Agranulocytosis... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Auditory hallucinations | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
|
Behaviour abnormal | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
|
Disorientation | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
|
Fear | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
|
Visual hallucinations | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
|
Insomnia | Disc. AE | 800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Condition: lower urinary infection Age Group: 86 years Sex: F Population Size: 1 Sources: |
Leucopenia | 1600 mg multiple, oral Recommended Dose: 1600 mg Route: oral Route: multiple Dose: 1600 mg Co-administed with:: TRIMETHOPRIM(320 mg; daily) Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: renal transplantation Age Group: adult Population Size: 14 Sources: |
|
Granulocytopenia | 1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(240 mg; 2/day) Sources: amphotericin B(800 mg; day) |
unhealthy, mean age 47 years n = 26 Health Status: unhealthy Condition: acute nonlymphocytic leukaemia Age Group: mean age 47 years Population Size: 26 Sources: |
|
Allergic reaction | 3.8% Disc. AE |
1200 mg 2 times / day multiple, oral Recommended Dose: 1200 mg, 2 times / day Route: oral Route: multiple Dose: 1200 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(240 mg; 2/day) Sources: amphotericin B(800 mg; day) |
unhealthy, mean age 47 years n = 26 Health Status: unhealthy Condition: acute nonlymphocytic leukaemia Age Group: mean age 47 years Population Size: 26 Sources: |
Skin rash | 4.9% Disc. AE |
800 mg 2 times / day multiple, oral Recommended Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Co-administed with:: TRIMETHOPRIM(160 mg; 2/day) Sources: |
unhealthy, mean age 58 years n = 41 Health Status: unhealthy Condition: urinary infection Age Group: mean age 58 years Sex: M+F Population Size: 41 Sources: |
Agranulocytosis | 9.9% | 1200 mg multiple, oral (mean) Studied dose Dose: 1200 mg Route: oral Route: multiple Dose: 1200 mg Co-administed with:: TRIMETHOPRIM(240 mg; day) Sources: |
unhealthy, median age 69 years n = 91 Health Status: unhealthy Condition: septicemia Age Group: median age 69 years Sex: M+F Population Size: 91 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 5.0 |
moderate [Ki 271 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12019187/ Page: 4.0 |
unlikely |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9602961/ Page: 4.0 |
yes | |||
Sources: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2125.1996.40110.x#page=3 Page: 3.0 |
yes | yes (co-administration study) Comment: ketoconazole did not inhibit hydroxylamine formation or any route of SMX metabolism; fluconazole decreased 5OH-SMX-acetate by64.0% Sources: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2125.1996.40110.x#page=3 Page: 3.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Neonatal mouse model: review of methods and results. | 2001 |
|
Phenotyping of Campylobacter jejuni and Campylobacter coli by a quantitative antibiogram [MIC] typing scheme using Euclidean distances [QATED]. | 2001 |
|
Molecular characterization of Salmonella weltevreden isolated from poultry: evidence of conjugal transfer of plasmid and antibiotic resistance. | 2001 |
|
Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single- and multiple-dose administration to healthy pigs. | 2001 Aug |
|
Hydrogen bonding in sulfonamides. | 2001 Dec |
|
Resistance to trimethoprim-sulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates. | 2001 Dec |
|
Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons. | 2001 Dec |
|
Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. | 2001 Dec |
|
Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia. | 2001 Feb |
|
Treatment of cat-scratch disease. | 2001 Feb |
|
Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. | 2001 Feb 1 |
|
In vitro quantitative analysis of (3)H-uracil incorporation by Sarcocytis neurona to determine efficacy of anti-protozoal agents. | 2001 Feb 26 |
|
Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. | 2001 Jul |
|
Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis? | 2001 Jun |
|
Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. | 2001 Jun |
|
Transition of drug susceptibilities of Vibrio cholerae O1 in Lao People's Democratic Republic. | 2001 Mar |
|
Topical bactrim versus trimethoprim and sulfonamide against nocardia keratitis. | 2001 Mar |
|
Multiple actinomyces brain abscesses: case report. | 2001 Mar |
|
Randomized intervention study comparing several regimens for the treatment of moderate anemia among refugee children in Kigoma Region, Tanzania. | 2001 Mar-Apr |
|
A suspected case of primary cutaneous actinomycosis on the buttock. | 2001 May |
|
Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice. | 2001 May |
|
Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. | 2001 May |
|
Plasmid mediated antibiotic resistance in Klebsiella pneumoniae. | 2001 Oct |
|
Antimicrobial susceptibility and plasmids from Escherichia coli isolated from rats. | 2001 Oct |
|
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. | 2001 Oct |
|
CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). | 2001 Sep |
|
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen. | 2002 Apr |
|
Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. | 2002 Apr |
|
Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. | 2002 Apr 15 |
|
Determination of anti-microbial susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. | 2002 Feb |
|
Folic acid antagonism of sulfa drug treatments. | 2002 Feb |
|
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. | 2002 Jan |
|
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. | 2002 Jun |
|
Study of different off-line sample processing procedures and the measurement of antibiotic and antiviral levels in human serum by high-performance liquid chromatography. | 2002 Jun 25 |
|
Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses. | 2002 Mar |
Sample Use Guides
The usual adult dosage in the treatment of urinary tract infections and otitis media is 1 DS (double strength) tablet (each DS tablets contains 800 mg sulfamethoxazole and 160 mg trimethoprim) every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 DS tablet every 12 hours for 14 days. The recommended dosage for treatment of patients with documented Pneumocystis jiroveci pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. The recommended dosage for prophylaxis in adults is 1 DS tablet daily. For the treatment of traveler’s diarrhea, the usual adult dosage is 1 DS tablet every 12 hours for 5 days.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:04:28 UTC 2023
by
admin
on
Wed Jul 05 23:04:28 UTC 2023
|
Record UNII |
JE42381TNV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.4 (SUL/TRI)
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2 (SUL/TRI)
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-ATC |
J01EE01
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-VATC |
QJ01EQ11
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-VATC |
QJ01EW11
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
NCI_THESAURUS |
C29739
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
LIVERTOX |
NBK547937
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
NDF-RT |
N0000175504
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-ATC |
J04AM08
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
WHO-ATC |
J01EC01
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
||
|
NDF-RT |
N0000008048
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Sulfamethoxazole
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
9332
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
DTXSID8026064
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
JE42381TNV
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
SULFAMETHOXAZOLE
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
2514
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
SUB10711MIG
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
C47737
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
10180
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | RxNorm | ||
|
SULFAMETHOXAZOLE
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | Description: A white or yellowish white, crystalline powder; odourless. Solubility: Very slightly soluble in water; soluble in 50 parts of ethanol (~750 g/l) TS and in 3 parts of acetone R. Category: Antibacterial. Storage: Sulfamethoxazole should be kept in a well-closed container, protected from light. Definition: Sulfamethoxazole contains not less than 99.0% and not more than 101.0% of C10H11N3O3S, calculated with reference to the dried substance. | ||
|
N0000185504
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | Cytochrome P450 2C9 Inhibitors [MoA] | ||
|
211-963-3
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
D013420
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
3186
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
CHEMBL443
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
147832
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
5329
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
1631001
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
1386
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
100000092618
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
JE42381TNV
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
DB01015
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
723-46-6
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
Trimethoprim-Sulfamethoxazole
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | |||
|
M10320
Created by
admin on Wed Jul 05 23:04:28 UTC 2023 , Edited by admin on Wed Jul 05 23:04:28 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE REACTIVE TYPE->PARENT |
|
||
|
METABOLITE REACTIVE TYPE->PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||